Introduction
Crohn's disease (CD) and ulcerative colitis (UC) are now common causes of gastrointestinal morbidity in the United Kingdom, 1,2 and although the incidence of CD may have reached a plateau in other regions of the world it has continued to rise in Scottish children. 3, 4 While the aetiology of CD remains unknown, it is now clear that gene-environment interactions are central to understanding disease pathogenesis. 5 Detailed evaluation of the susceptibility locus on chromosome 16 has lead to the identification of the inflammatory bowel disease (IBD)1 gene as NOD2 (caspase recruitment domain (CARD)15). 6, 7 NOD2/CARD15 contains a highly conserved CARD linked to a nucleotide-binding domain, which are thought to regulate apoptosis and nuclear factor-kB (NFkB) activation. The C-terminal domain of NOD2/CARD15 comprises a leucine-rich repeat (LRR) region, which has sequence homology with a number of plant disease resistance genes, the toll and toll-like receptor (TLR) gene superfamilies.
The importance of this gene in CD has come under intense scrutiny, but a number of areas of controversy remain unresolved. The contribution of the gene has been studied in many diverse populations, [7] [8] [9] [10] [11] with positive associations in up to 50% of CD patients. 12 However, data from Japanese, Korean and African-American individuals have not shown an association, [13] [14] [15] and there are now clear differences between Ashkenazi Jewish and nonJewish populations. 16, 17 Most recent data from Ireland and Northern Europe report relatively low allelic frequencies in healthy controls and CD patients (Table 1) and raise the possibility of heterogeneity within European populations of distinct ancestry. [22] [23] [24] [25] Further controversy has arisen in attempts to relate NOD2/CARD15 genotype to phenotype and studies have been confounded the validity of subclassifications used. 27 The age at diagnosis, location of disease and disease behaviour have been adopted in the Vienna classification, 28 and data have emerged to suggest that this clinical classification bears further examination. 29 Nonetheless, it is apparent that genotype-phenotype relationships exist. Lesage et al 12 suggested that patients carrying two variant copies of the CARD15/NOD2 gene are at increased risk of ileal involvement, early age at diagnosis and fibrostenotic behaviour of disease. Ahmad et al, 11 Cuthbert et al, 10 and others 9, 19, 22, 25 have also suggested that carriage of allelic variants is associated with ileal involvement in CD. However, as further data emerge, the primary genotype-phenotype relationship remains controversial and most limited by the quality of phenotypic data.
The discovery of NOD2/CARD15 has focused interest on the regulation of innate immune responses and apoptosis. Functional studies have shown that NOD2/ CARD15 is a general sensor of peptidoglycan that is mediated through the recognition of muramyl dipeptide (MDP). 30 Although it remains uncertain as to how/ whether the NOD2/CARD15 protein interacts with other protein families involved in the innate immune response, genes encoding these regulatory proteins bear investigation as potential susceptibility genes. The TLR family is involved in the recognition of pathogen-associated molecular patterns by the immune system. TLR4 recognises lipopolysaccharide using the extracellular LRR domain. 31 Recognition of LPS by TLR4 requires several accessory molecules. LPS is first bound to a serum protein, LBP (LPS-binding protein), which functions by transferring LPS monomers to CD14, a highaffinity LPS receptor. MD-2, a protein that lacks a transmembrane region and is expressed on the cell surface in association with TLR4 32 complexes with these components.
Variations in TLR4 receptor distribution have been described in patients with IBD. 33 Moreover, a singlenucleotide polymorphism (SNP) of the TLR4 gene (A299G) that affects in vitro activity has been associated with airway hyporesponsiveness following LPS stimulation in humans. 34 The human CD14 gene lies on the long arm of chromosome 5 (5q31.1), close to an area of reported linkage in CD (IBD5). 35 Membrane-bound CD14 is expressed on monocytes and macrophages, and the expression of CD14 on mucosal macrophages is upregulated in active IBD. 36, 37 A common functional promoter region polymorphism (T-159C) of the CD14 gene has been identified 38 and a weak association with both CD and UC has been demonstrated. [39] [40] [41] In the present study, we have investigated the contribution of the three common NOD2/CARD15 variants in determining susceptibility and phenotype in a large cohort of Scottish patients with well-characterised CD and UC. We have gone on to compare these data with a cohort of Irish patients who may have common Celtic ancestry, in order to explore the similarity in genetic predisposition. In view of the relatively low contribution of these variants, compared with other European populations, an investigation of the contribution of the functional polymorphisms of genes encoding TLR4 and CD14 was undertaken.
Results
Disease susceptibility NOD2/CARD15. In the Scottish CD population, simple heterozygotes (P ¼ 0.031, odds ratio (OR) 1.7 (CI 1.0-2.9)) and compound heterozygotes (P ¼ 0.003) were at more risk of CD than controls. Homozygotes, however, did not carry an additional risk for CD (P ¼ 0.889) ( Table 2 ). The NOD2/CARD15, TLR4 and CD14 in Crohn's disease IDR Arnott et al population attributable risk percent (PAR%) for CD in the Scottish population overall was 11.0% for possession of one or more variant alleles at any of the three sites. CD allelic frequencies of the 1007fsinsC, G908R and R702W were 4.6, 1.8 and 7.2%, respectively, as compared to frequencies of 1.4, 0.2 and 5.5% in the control group. The 1007fsinsC (P ¼ 0.003, OR 3.4 (CI 1.4-7.9)) and G908R (P ¼ 0.008, OR 9.7 (CI 1.2-15.3)) but not the R702W (P ¼ 0.269, OR 1.4 (CI 0.9-2.4)) differed between CD and controls ( Table 3) .
As a relatively low frequency of variant alleles was observed, we have performed a comparison of allelic frequencies in our population and previously published populations from different geographical locations. This demonstrates that the common NOD2/CARD15 variants are significantly less common in Scottish CD than in documented populations from North America (Po0.00001), 8 Europe (Po0.00001) 7 and the United Kingdom (P ¼ 0.0012) 11 (Table 4) . When compared with a population from Northern Europe, 22 these differences were not seen. Comparison of control allelic frequencies between these groups shows no differences for the 1007insC. The G908R was seen more frequently in the control group of Ahmad et al 11 (P ¼ 0.0327) and R702W is seen less frequently in the control group of Helio et al
The P268S allelic frequency did not differ between CD and controls (28.7 vs 26%, P ¼ 0.42), but variants of this allele did occur in association with the other NOD2/ CARD15 variants.
In UC, no overall association with NOD2/CARD15 was present, although variant G908R alleles are seen more frequently when compared to the control group (Po0.0001, OR ¼ 10.7 (CI 1.3-42.0)). The R702W allele was less prevalent in UC patients than either HC group (Table 3 ).
In the Irish population simple heterozygotes were seen more commonly in the CD group (29/113 vs 6/59, P ¼ 0.0054, OR ¼ 3.0 (CI 1.2-7.8)), but there was no increase in the frequency of compound heterozygotes or homozygotes (Table 5A ). The PAR% for carriage of any variant in the Irish population is 18.3%. NOD2/CARD15 allelic frequencies did not differ between CD and HC, although a trend was apparent for each allele. The CD allelic frequency of 1007fsinsC, G908R and R702W were 3.0, 2.2 and 9.7% compared to 0.9, 0.9 and 5.1% in HC (Table 5B) .
The allelic frequencies of 1007fsinsC (P ¼ 0.2965), G908R (P ¼ 0.9510), R702W (P ¼ 0.3310) and P268S (P ¼ 0.8165) did not differ between Scottish and Irish CD. When allelic frequencies of Irish CD patients are compared with those of North American, European and UK populations there are significantly fewer variants of the 1007fsinsC (Po0.00001) and G908R (0.014), but there is no difference in the frequency of R702W (P ¼ 0.5012). TLR4 and CD14 polymorphism: Carriage of the T-159C promoter variant in the CD14 gene was associated with early age at diagnosis. This is manifest as a preponderance of variants in the first and second age quartile (133/230 mutations in the first and second age quartile vs 103/228 mutations in the third and fourth quartiles, w 2 ¼ 6.8, P ¼ 0.009, RR ¼ 1.29 (CI 1.15-2.41)).
Weak associations were also identified with inflammatory eye disease and variants of both A299G (mutations present in 6/28 alleles with iritis vs 39/408 without, P ¼ 0.046, RR 2.59 (CI 0.99-6.75)) and T-159C (mutations present in 8/28 with iritis vs 213/424, P ¼ 0.0157, RR 0.4 (CI 0.17-0.92)).
There was no association of TLR4 A299G with age at diagnosis. In addition, A299G and T-159C were not associated with sex, anatomical distribution of disease, disease behaviour at diagnosis, progression of disease behaviour over time, intestinal resection, family history of IBD or the extraintestinal manifestations of skin or joints.
Discussion
We have performed the first analysis of genetic susceptibility to CD in Scotland. This is a country with a high incidence of CD and a stable population with a relatively little admixture. 42 We have shown that the contribution of the common NOD2/CARD15 variants to CD susceptibility is significantly less than in previously reported series from Europe and North America. The PAR%, an indication of the contribution of a mutation to the disease in a certain community, is an illustration of the observed differences. The PAR% in the present study is 11.0% compared to 27% in Oxford 11 and Los Angeles 8 and 33.2% in the initial study of Hugot et al. 7 This is also lower than the 12.9% from the data of Helio et al 22 and thus the lowest reported figure from Europe or North America. We have gone on to compare these data with a cohort of Irish patients who may share common ancestry. Although the Irish CD population showed a similar overall pattern of allelic frequencies, it is of some note that the derived PAR% in the Irish cohort was 18.3%. The small size of the Irish cohort makes extrapolation of these results to the wider population difficult; there may also be difficulties with the ability to detect other relevant findings and confirmation of these findings in this population may be necessary.
Six of the eight detailed studies in Europe have shown allelic frequencies for the 1007fsinC in excess of 6%. It is of interest that the other two studies, 22, 23 with a low contribution of the NOD2/CARD15 variants, have involved Northern European populations in Ireland and Finland. Although this comparison was not a primary objective of the study (equity of sample representation cannot be assured), comparisons of allelic frequencies between populations of Northern European, North American and United Kingdom origin have shown substantial differences and are likely to be a real observation.
We feel that it is now clear from the published data that there is a strong evidence for regional heterogeneity within Europe in the contribution of NOD2/CARD15 to disease susceptibility, and we suggest that these observations are likely to reflect differing founder populations. This is consistent with NOD2/CARD15 heterogeneity already demonstrated in healthy populations. 43 Recent molecular studies involving maternally transmitted mitochondrial DNA have produced new insights into the relative contribution of Norse and Celtic in North European populations. Genotyping provided confirmation that the origins of Scottish populations have predominant Scandinavian and Irish influences, consistent with the population history, and are dissimilar to populations from central, southern and Baltic regions. These have been complemented by a Y chromosome analyses in geographically distinct British Isles populations. 42 In addition to the Celtic influences in Scotland, Norwegian populations significantly influenced Scots from the northern isles. Although lowland Scots had some evidence of German/Danish influence, the Celtic origins in these peoples were, in fact, relatively stronger. The Y chromosome analysis has recently been complemented by data from a large Flemish cohort. This has suggested that paternal transmission of variant NOD2/ CARD15 alleles gave a five-fold greater chance of the child developing the disease compared to maternal transmission. 44 Like other studies, we have observed a significantly lower frequency of variant R702W alleles in patients with UC, but we have also shown a higher frequency of variant G908R alleles in this group. This has not thus far been reported and while the frequency is similar to that reported in other studies, it contrasts sharply to that in the control group and thus requires replication in a further cohort.
Despite a modest contribution to disease susceptibility, NOD2/CARD15 mutations do contribute to disease behaviour and many phenotypic associations previously documented have been replicated. We have confirmed the associations with early-onset disease 12, 23 and ileal disease distribution.
9-12,22,23, 25 The latter observation is strongest in patients with two variant alleles, consistent with the data of Lesage et al. 12 We have also seen a relatively weak association with perforating disease at diagnosis, but could not confirm the association with fibrostenosing disease. 8 We observed an association with IBD-associated peripheral arthritis; however, significance was not achieved following correction for multiple variables. It remains to be seen whether these findings will be replicated in detailed genotype-phenotype analysis in other populations. Type I and II peripheral arthropathies have been demonstrated to be clinically and genetically distinct entities associated with mutations with the HLA region. 45, 46 We have shown that the studied mutations in the TLR4 and CD14 genes do not contribute to disease susceptibility in CD. Much interest has surrounded TLR4 variants in the last 12 months, and studies from Europe available only in abstract form have reached mixed conclusions. Allelic frequency of the A299G mutation in the five published abstracts range from 8 to 13% with that in the controls of 5-15%. The interpretation of apparently discrepant case-control association data represents one of the most thorny issues in complex disease genetics at the present time. With the degree of heterogeneity affecting the NOD2/CARD15 gene as an illustration, it is difficult to fully reconcile all these discrepant data. Family-based association data or typing of random markers as a control for population stratification may help to define the contribution in each population. At present, it is conceivable that the positive conclusions in studies of the TLR4 gene have arisen as a result of real population-related heterogeneity, or alternatively, as an artefact of population stratification. The functional relevance of TLR4 mutations may be less secure following the identification of MDP as the ligand for NOD2/CARD15. 30 Although previous data from Germany have implicated the CD14 promoter variant in disease susceptibility, we could not confirm the T-159C mutation as a susceptibility gene for CD in our population. It is of some interest that this SNP is associated with earlier age of onset, as this variant maps to the IBD5 region, which in an early study was only of genome-wide significance in families with early-onset disease. 35 A more recent genotype-phenotype analysis of this region has not, however, confirmed this association. 47 In the present study, we have demonstrated that the common mutations in the NOD2/CARD15 gene have a low contribution to CD susceptibility in a Scottish population. The phenotypic consequences of these mutations do not differ between populations, being associated with early-onset disease and an ileal disease distribution. The A299G variant of the TLR4 gene and the T-159C of the CD14 gene were not associated with susceptibility to IBD.
The presented data suggest clear avenues for further work. Other genetic (and environmental) factors influencing disease susceptibility and behaviour in Northern European CD patients exist, out of the three variants of the NOD2/CARD15 gene studied. Indeed, in the study of Bairead et al, 23 the allelic frequency of the common NOD2/CARD15 mutations was similar to the presented data but fine mapping of the region of interest on chromosome 16 continued to show linkage with a MLOD score of 2.241. Full study of the NOD2/CARD15 gene in this population is required, and this will necessitate detailed mutation analysis of coding, and noncoding regions. If the overall contribution of NOD2/CARD15 remains low, the contribution of other candidate genes, both within the IBD1 region and out of this region, require to be assessed.
Patients and methods

Scottish patients
In all, 499 well-characterised white patients with IBD and 189 control subjects were assessed. All patients attended the IBD clinic at the Western General Hospital, Edinburgh. This is a tertiary referral centre for IBD in the South East of Scotland. The IBD group comprised 252 patients with CD and 247 with UC. The diagnosis of IBD adhered to the criteria of Lennard-Jones. 48 The age at diagnosis, location and behaviour were classified according to the Vienna classification. 28 Phenotypic data were collected by patient questionnaire, interview and casenote review and comprised demographics, date of onset and diagnosis, location, disease behaviour, extraintestinal manifestations, surgical operations, comorbid disease, smoking details, joint symptoms, family history and ethnicity. Informed consent was obtained from all patients and controls. The Medicine and Oncology Subcommittee of the Lothian Local Research Ethics Committee approved the study protocol.
CD group
The CD group consisted of 110 males and 142 females with a median age at diagnosis of 28 years (IQR 21-41 years). Full phenotypic data were available on 235 patients. Disease distribution at diagnosis comprised: ileal disease (L1) in 80 patients (34%), colonic disease (L2) in 91 (39%), ileal and colonic disease (L3) in 41 (17%) and upper GI disease (L4) in 23 (10%). In total, 60 patients (26%) had coexisting perianal disease, 149 (65%) had undergone prior surgical resection and 47 (20%) had a family history of IBD. The median disease duration was 141 months (IQR 79-242 months).
UC group
Clinical details were available on 232 of the UC group. The group consisted of 124 males and 108 females with a median age at diagnosis of 33 years (IQR 25-49 years).
Control subjects
The control group comprised 272 healthy subjects and contained both blood donors and actively recruited healthy controls. There were 142 males and 130 females with a median age at assessment of 38 years (IQR 27-50).
Irish patient cohort
The Irish CD group comprised 113 patients (77 females and 36 males) with a median age at diagnosis of 27.5 years (IQR [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . This corresponded to 38 patients diagnosed before the age of 40 years (A1) and 21 diagnosed after the age of 40 years (A2). At diagnosis, 32 patients had inflammatory disease behaviour (B1), 14 stricturing disease (B2) and 13 penetrating disease (B3). Again, according to the Vienna classification 25 had isolated ileal disease (L1), 24 isolated colonic disease (L2) and 10 had both ileal and colonic disease (B3). None were classified as having upper GI disease. Data were also available on 59 Irish healthy control subjects.
Methods
Genomic DNA was extracted from peripheral venous blood by a modified salting-out technique 49 and resuspended in 1 Â TE (10 mM Tris (pH 8.0), 1 mM EDTA (pH 8.0)) at a final concentration of 100 ng/ml. Four NOD2/ CARD15 variants were typed, R702W, G908R, 1007fsinsC and P268S. The A229G polymorphism of the TLR4 gene and the T-159C polymorphism of the CD14 gene were also typed. R702W was typed using restriction fragment length polymorphism (RFLP) PCR and Taqman and the P268S by RFLP PCR. All the others were typed by allelespecific PCR. All PCRs were carried out in a final volume of 20 ml with the reaction conditions: 1 Â PCR buffer (16 mM (NH 4 ) 2 SO 4 , 67mM Tris-HCl (pH 8.8), 0.01% Tween-20), 250 mM each of four dNTPs, 1 U Taq polymerase and 50 ng DNA. Variable amounts of primers and MgCl 2 concentrations were used (Table 7) . For the allelespecific PCR, wild-type and variant reactions were run separately. Each tube contained the two common primers and the wild-type or variant primer in the concentrations shown in Table 7B .
For all PCRs, 35 cycles of amplification were performed of 30 s at 921C, 30 s at the appropriate annealing temperature and 45 s at 721C, followed by a final extension of 721C for 5 min. RFLP PCRs were digested overnight at 371C after the addition of 2.5 ml manufacturer's 10 Â restriction buffer and the appropriate restriction enzyme (Table 7A ). All PCRs were run on 1.5% agarose gels with the exception of the R702W polymorphism that was run on 3% NewSieve 3 : 1 agarose. Gels were stained with EtBr and viewed under ultraviolet light. An image was recorded digitally.
Statistics
Each genotype and allele was analysed for association with CD overall and disease phenotype. Allele and genotype frequencies were determined for all polymorphisms. All alleles were shown to be in HardyWeinberg equilibrium. Genotype-phenotype associations were analysed by w 2 test using Minitab statistical software package (Minitab Ltd., Coventry, UK). A Bonferroni correction was applied for multiple comparisons to all novel associations. No correction was applied to alleles previously reported to be associated with CD. To identify significant independent variables associated with genotype, all variables that were significantly associated with genotype on univariate analysis were entered simultaneously into a multiple logistic regression analysis. The PAR% was defined as the excess rate of disease in individuals with a mutation compared with those without. This was estimated by the method of Schlesselman and Stolley, 50 which estimates PAR% as equal to attributable risk as a function of the prevalence in the exposed population, divided by incidence of IBD in the population. To calculate this, the prevalence of CD was estimated at 100/100 000 and the frequency of all alleles in the control population was assumed to reflect that of the general population.
